A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease

Detalhes bibliográficos
Autor(a) principal: Oliveira,Ione Ayala Gualandi de
Data de Publicação: 2019
Outros Autores: Caetano,Rosângela, Steffen,Ricardo Ewback, Biz,Aline Navega
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Geriatria e Gerontologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232019000400303
Resumo: Abstract Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.
id UFRJ-10_5108f8a020b55b133dafbd510352fdbc
oai_identifier_str oai:scielo:S1809-98232019000400303
network_acronym_str UFRJ-10
network_name_str Revista Brasileira de Geriatria e Gerontologia
repository_id_str
spelling A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s diseaseAlzheimer DiseaseMemantineCost and Cost AnalysisReviewAbstract Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.Universidade do Estado do Rio Janeiro2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232019000400303Revista Brasileira de Geriatria e Gerontologia v.22 n.4 2019reponame:Revista Brasileira de Geriatria e Gerontologiainstname:Universidade do Estado do Rio de Janeiro (UERJ)instacron:UFRJ10.1590/1981-22562019022.190002info:eu-repo/semantics/openAccessOliveira,Ione Ayala Gualandi deCaetano,RosângelaSteffen,Ricardo EwbackBiz,Aline Navegaeng2020-03-20T00:00:00Zoai:scielo:S1809-98232019000400303Revistahttp://revista.unati.uerj.br/scielo.php?script=sci_serial&pid=1809-9823&lng=pt&nrm=isohttps://old.scielo.br/oai/scielo-oai.php||revistabgg@gmail.com1981-22561809-9823opendoar:2020-03-20T00:00Revista Brasileira de Geriatria e Gerontologia - Universidade do Estado do Rio de Janeiro (UERJ)false
dc.title.none.fl_str_mv A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
title A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
spellingShingle A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
Oliveira,Ione Ayala Gualandi de
Alzheimer Disease
Memantine
Cost and Cost Analysis
Review
title_short A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
title_full A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
title_fullStr A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
title_full_unstemmed A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
title_sort A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
author Oliveira,Ione Ayala Gualandi de
author_facet Oliveira,Ione Ayala Gualandi de
Caetano,Rosângela
Steffen,Ricardo Ewback
Biz,Aline Navega
author_role author
author2 Caetano,Rosângela
Steffen,Ricardo Ewback
Biz,Aline Navega
author2_role author
author
author
dc.contributor.author.fl_str_mv Oliveira,Ione Ayala Gualandi de
Caetano,Rosângela
Steffen,Ricardo Ewback
Biz,Aline Navega
dc.subject.por.fl_str_mv Alzheimer Disease
Memantine
Cost and Cost Analysis
Review
topic Alzheimer Disease
Memantine
Cost and Cost Analysis
Review
description Abstract Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232019000400303
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232019000400303
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1981-22562019022.190002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Universidade do Estado do Rio Janeiro
publisher.none.fl_str_mv Universidade do Estado do Rio Janeiro
dc.source.none.fl_str_mv Revista Brasileira de Geriatria e Gerontologia v.22 n.4 2019
reponame:Revista Brasileira de Geriatria e Gerontologia
instname:Universidade do Estado do Rio de Janeiro (UERJ)
instacron:UFRJ
instname_str Universidade do Estado do Rio de Janeiro (UERJ)
instacron_str UFRJ
institution UFRJ
reponame_str Revista Brasileira de Geriatria e Gerontologia
collection Revista Brasileira de Geriatria e Gerontologia
repository.name.fl_str_mv Revista Brasileira de Geriatria e Gerontologia - Universidade do Estado do Rio de Janeiro (UERJ)
repository.mail.fl_str_mv ||revistabgg@gmail.com
_version_ 1750128437109981184